Penn Medicine, University of Pennsylvania Health System account plan
Innovative healthcare research education
At a glance
Penn Medicine is the University of Pennsylvania's academic health system, with $10,204,994 thousand of FY2025 net patient service revenue.
Penn Medicine is the governance structure of the University of Pennsylvania that oversees its health system (UPHS) and the Perelman School of Medicine, combining clinical care, research and education. UPHS is not a separate legal entity: it is operated by the Trustees of the University, a not-for-profit founded in 1740. Its hospitals include the Hospital of the University of Pennsylvania, Penn Presbyterian, Pennsylvania Hospital, Chester County, Lancaster General Health, Princeton HealthCare System and, since April 1, 2025, Penn Medicine Doylestown Health. In FY2025 (year ended June 30, 2025) UPHS earned net patient service revenue of $10,204,994 thousand and an operating excess of $246,734 thousand; headcount is not stated in the documents. Kevin Mahoney is CEO of the health system and Julia Puchtler its CFO.
Business units
University of Pennsylvania Health System (UPHS)
net patient service revenue $10,204,994 thousand in FY2025Penn Medicine's clinical arm: hospitals, the Clinical Practices of the University of Pennsylvania, Clinical Care Associates and Wissahickon Hospice. Expenses grew faster than revenue in FY2025, so the operating excess fell to $246,734 thousand from $278,488 thousand. Managed care was 41% of net patient service revenue and Medicare 35%.
Penn Medicine Doylestown Health
Doylestown Hospital, Doylestown Health Physicians and the Doylestown Health Foundation joined Penn Medicine on April 1, 2025 through a member substitution, with no consideration exchanged; UPHS recorded $124,952,000 of contribution income.
UPHS ambulatory pharmacy
$1,443,726 thousand of other income in FY2025The ambulatory pharmacy's income grew from $1,091,816 thousand in FY2024 and was a main driver of the rise in other income.
Captive insurance (Franklin Casualty and Quaker Insurance)
A wholly owned risk retention group and offshore captive that, with Mcare and commercial insurers, make up the medical professional liability programme; they held $226,557 thousand of assets for UPHS at June 30, 2025.
Perelman School of Medicine and Academic Component
The University's education and research side, which receives transfers from UPHS ($419,275,000 in FY2025) to further PSOM research and education. Penn Medicine research produced CAR T-cell therapy, the mRNA technology behind COVID-19 vaccines and gene therapies for blindness.
Strategic priorities
- Technology and AI in care delivery
- The CEO names AI, machine learning and automation to streamline diagnostics, treatment plans and routine tasks, and to remove administrative burdens from clinicians.
- Location-flexible and virtual care
- Penn Medicine is investing in outpatient care, telehealth and home care, and says care will be more virtual, with patients more open to staying close to home.
- Regional growth closer to home
- It added a seventh acute care hospital and names a new outpatient center in Montgomeryville, a proton therapy center in West Philadelphia, expanded cancer care in New Jersey and a mobile mammogram van.
- Personalized medicine and translational research
- Leaders tie research to clinical care, citing the Smilow Center for Translational Research, and prioritise treatments tailored with genetics and biotechnology.
- Portfolio approach to investment
- The CFO funds projects as a portfolio that must meet mission and financial criteria together, phasing projects without an immediate return so they can change course.
Investments and deals
- Capital spending
- The University's purchases of property, plant and equipment were $979,162 thousand in FY2025, with construction-in-progress of $760,649 thousand and capital commitments of approximately $452,073,000 at June 30, 2025.
- New financing for the health system
- After year end, Series A of 2025 bonds of $318,525,000 reimbursed UPHS $179,000,000 of capital expenditure, UPHS raised its revolving credit line to $200,000,000, added a second $100,000,000 line, and set up a taxable commercial paper programme of up to $300,000,000.
- Doylestown Health integration
- Penn Medicine took on $467,806 thousand of assets and $316,029 thousand of liabilities with Doylestown Health, including $174,814 thousand of long-term debt.
- HUP-Cedar Avenue
- Penn Medicine took over operations at HUP-Cedar Avenue in West Philadelphia after Mercy Philadelphia closed, adding an on-site food pantry and converting unused space into a ground-floor ambulatory practice.
Challenges and risks
- Costs rising faster than revenue
- UPHS total expenses rose to $11,748,880 thousand from $10,620,592 thousand in FY2025, compressing the operating excess.
- Reimbursement uncertainty
- Medicare and Medicaid rules are described as extremely complex, and third-party revenue is subject to audit and retroactive adjustment; the Aetna agreement rolled over only through June 30, 2026.
- Malpractice exposure
- A jury awarded $182,738,000 against UPHS in a fiscal year 2023 malpractice case, which UPHS has appealed; the gross professional liability was $856,770,000 at June 30, 2025.
- Federal funding and new taxes
- Research depends largely on governmental sources, and from fiscal year 2026 the University faces a 21% excise tax on executive pay over $1,000,000 and a 1.4% to 8% tax on net investment income.
What leadership says
“Healthcare is going to be more virtual, more telemedicine, and we're going to keep leaning in”
“we're focused on future-proofing so that we can adapt to unexpected challenges like funding changes, economic shifts and other pressures”
“You can't do only things that don't have a return on investment ... It's a portfolio. So you're going to need things that do generate a return so that you can generate returns to fund the things that don't.”
“Looking ahead, technology will transform the way we deliver care and work.”
Where a supplier can help
- Clinical AI and administrative automation
- Tied to the technology and AI priority: tools that cut documentation and routine tasks for clinicians match the CEO's goal of removing administrative burdens, and help with costs rising faster than revenue.
- Telehealth and home care platforms
- Tied to the location-flexible care priority: virtual visit, remote monitoring and home care vendors fit a system that plans to keep leaning into telemedicine.
- Outpatient and facility build-out
- Tied to regional growth and capital spending: equipment, construction and facility technology suppliers can support new outpatient, proton therapy and cancer care sites; phased proposals suit the CFO's portfolio approach.
- Revenue cycle and payer analytics
- Tied to reimbursement uncertainty: revenue cycle, denials and value-based contract analytics help with complex Medicare and Medicaid rules and the Aetna and Independence Blue Cross contracts.
- Integration of Doylestown Health
- Tied to the Doylestown Health integration: IT, supply chain and clinical systems integration services can help bring a newly joined hospital onto Penn Medicine's platforms.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Penn Medicine, University of Pennsylvania Health System?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- University of Pennsylvania (incl. University of Pennsylvania Health System): Consolidated Financial Statements FY2025 (year ended June 30, 2025) and Uniform Guidance reports
- Penn Medicine is not a separate company: the University of Pennsylvania Health System (UPHS) is operated by the Trustees of the University of Pennsylvania, and "Penn Medicine" is the governance structure the Trustees formed to oversee UPHS together with the Perelman School of Medicine (PSOM). The audited statements that cover it are the University's consolidated financial statements (PwC, unmodified opinion dated September 25, 2025).
- UPHS FY2025 (year to June 30, 2025): net patient service revenue $10,204,994 thousand (FY2024: $9,476,064 thousand), other revenue and support $1,790,620 thousand, total expenses $11,748,880 thousand, and excess of revenue over expenses from operations $246,734 thousand, down from $278,488 thousand.
- UPHS total assets were $16,038,297 thousand and net assets $10,020,272 thousand at June 30, 2025; UPHS debt obligations were $2,549,574 thousand.
- The system grew by affiliation: Doylestown Health became Penn Medicine Doylestown Health (PMDH) on April 1, 2025 through a member substitution with no consideration, adding $467,806 thousand of assets and $316,029 thousand of liabilities.
- Payer mix of net patient service revenue in FY2025: Medicare 35%, managed care 41%, Medicaid 12%, Independence Blue Cross 9% (15% in FY2024), commercial 2%, self pay 1%. The IBC agreement was extended to June 30, 2028; the Aetna agreement rolls over through June 30, 2026.
- UPHS ambulatory pharmacy income rose to $1,443,726 thousand from $1,091,816 thousand; hospital and physician practices account for $11,707,103 thousand of the University's $16,445,321 thousand total operating expense.
- Risks named: a $182,738,000 jury award in a medical malpractice case (under appeal), a gross malpractice liability of $856,770,000, complex Medicare/Medicaid rules, and the One Big Beautiful Bill Act's excise taxes from FY2026.
- Liquidity actions after year end: UPHS raised its revolving credit line to $200,000,000, added a second $100,000,000 line, and set up a taxable commercial paper programme of up to $300,000,000 (August 2025).
- At Penn Medicine, evolving patient needs guide expansion (The Daily Pennsylvanian, interviews with CEO Kevin Mahoney and CFO Julia Puchtler)
- Daily Pennsylvanian feature (September 7, 2026) built on interviews with UPHS CEO Kevin Mahoney, CFO Julia Puchtler and HUP-Cedar Avenue Executive Director Sindhu Srinivas about how Penn Medicine chooses what to build.
- Mahoney calls the Smilow Center for Translational Research a "physical manifestation of our integrated mission". It puts researchers next to clinicians, and he cites the CAR T-cell work of Carl June and David Porter as an idea that grew from informal contact.
- The Clifton Center for Medical Breakthroughs (opened October 2021) was built "to be a hospital of the future": all 504 beds can become ICU beds, which added an estimated 5% to 7% to construction costs.
- Penn tested the design on a 30,000-square-foot mock-up of half a hospital floor, filmed with GoPro cameras, and changed door placement and hallway lengths as a result.
- Mahoney describes care as "location-flexible" across hospitals, outpatient clinics, homes and virtual visits: "Healthcare is going to be more virtual, more telemedicine, and we're going to keep leaning in"
- CFO Puchtler treats investment as a portfolio. Projects that earn a return fund the ones that do not, and projects are phased so Penn can change course.
- At HUP-Cedar Avenue (the former Mercy Philadelphia site), Penn added community partnerships, a food pantry and a renovated ground-floor ambulatory practice.
- The article reports that the Health System brought in over two-thirds of Penn's total revenue last year.
- Q&A with Kevin Mahoney, CEO of Penn Medicine (City & State Pennsylvania, sponsored content)
- Sponsored Q&A with Kevin Mahoney, CEO of Penn Medicine, published by City & State Pennsylvania on July 28, 2025 ("edited and condensed for length and clarity").
- His first focus is "Using technology to shape the future of healthcare": AI, machine learning and automation for diagnostics, treatment plans and routine tasks.
- Other priorities he names: personalized medicine (genetics, biotechnology), telemedicine and digital health, and fewer administrative burdens for clinicians.
- He wants to help people "start their careers faster, more affordably, and with more flexibility". This is a workforce pipeline theme.
- On changing federal research funding, he says Penn Medicine is "focused on future-proofing" against funding changes, economic shifts and other pressures. He cites CAR T cell therapy, mRNA vaccine technology and gene therapies for blindness as fruits of federal support.
- Growth: a seventh acute care hospital added, and investment in outpatient care, telehealth and home care.
- Projects named: a new outpatient center in Montgomeryville, a proton therapy center in West Philly, expanded cancer care in New Jersey, and a mobile mammogram van.
Questions about Penn Medicine, University of Pennsylvania Health System
What is Penn Medicine?
Penn Medicine is the University of Pennsylvania structure that oversees its health system (UPHS) and the Perelman School of Medicine, coordinating clinical care, research and education.
What is Penn Medicine's revenue?
In FY2025 (year ended June 30, 2025) UPHS earned net patient service revenue of $10,204,994 thousand and other revenue and support of $1,790,620 thousand, with an operating excess of $246,734 thousand.
Who leads Penn Medicine?
Kevin Mahoney is CEO of the University of Pennsylvania Health System and Julia Puchtler is its Senior Vice President and CFO; the Trustees of the University govern it.
What is Penn Medicine's strategy?
Its leaders prioritise AI and automation, location-flexible and virtual care, regional growth through outpatient sites and new hospitals, and translational research tied to patient care.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)